Brief: IVERIC Bio Announces Completion Of Rolling NDA Submission To FDA For Avacincaptad Pegol
20/12/2022 12:34
Dec 20 (Reuters) - IVERIC bio Inc ISEE.O :
* IVERIC BIO ANNOUNCES COMPLETION OF ROLLING NDA SUBMISSION
TO FDA
FOR AVACINCAPTAD PEGOL FOR THE TREATMENT OF GEOGRAPHIC ATROPHY
Source text for Eikon: ID:nBw7dNNFma
Further company coverage: ISEE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IVERIC bio
See all newsBrief: Astellas Pharma Inc - Astellas Completes Acquisition Of Iveric Bio
Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
Iveric Bio Inc Reports Results For The Quarter Ended In March: Earnings Summary
The end of cheap credit could hurry Japanese M&A
U.S. STOCKS ON THE MOVE-US banks, Biomea Fusion, Tutor Perini